about
Synthesis and in vitro evaluation of novel morpholinyl- and methylpiperazinylacyloxyalkyl prodrugs of 2-(6-methoxy-2-naphthyl)propionic acid (Naproxen) for topical drug deliveryDesign, synthesis and in vitro evaluation of novel water-soluble prodrugs of buparvaquone.Synthesis, in vitro and in vivo characterization of novel ethyl dioxy phosphate prodrug of propofol.Prodrugs--from serendipity to rational design.Diclofenac readily penetrates the cerebrospinal fluid in children.Prodrugs: design and clinical applications.Prodrug approaches for CNS deliveryCytochrome P450-activated prodrugs: targeted drug delivery.Prodrugs - an efficient way to breach delivery and targeting barriers.Prodrugs - Recent approvals and a glimpse of the pipeline.Amino Acid Promoieties Alter Valproic Acid Pharmacokinetics and Enable Extended Brain Exposure.Evaluation of novel imidazotetrazine analogues designed to overcome temozolomide resistance and glioblastoma regrowth.Amino acid ester prodrugs conjugated to the α-carboxylic acid group do not display affinity for the L-type amino acid transporter 1 (LAT1).Prodrugs in medicinal chemistry and enzyme prodrug therapies.Design, synthesis, and evaluation of novel cyclic phosphates of 5-aminosalicylic acid as cytochrome p450-activated prodrugs.In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates.Midazolam exhibits characteristics of a highly permeable P-glycoprotein substrate.Brain pharmacokinetics of ganciclovir in rats with orthotopic BT4C glioma.Brain uptake of ketoprofen-lysine prodrug in rats.Synthesis, stability and in vitro dermal evaluation of aminocarbonyloxymethyl esters as prodrugs of carboxylic acid agents.Synthesis and antileishmanial activity of novel buparvaquone oxime derivatives.Inefficient central nervous system delivery limits the use of ibuprofen in neurodegenerative diseases.Design, synthesis and brain uptake of LAT1-targeted amino acid prodrugs of dopamine.The first bioreversible prodrug of metformin with improved lipophilicity and enhanced intestinal absorption.Glucose promoiety enables glucose transporter mediated brain uptake of ketoprofen and indomethacin prodrugs in rats.How readily does ketorolac penetrate cerebrospinal fluid in children?Large neutral amino acid transporter enables brain drug delivery via prodrugs.Evaluation of hydroxyimine as cytochrome P450-selective prodrug structure.Cerebrospinal fluid distribution of ibuprofen after intravenous administration in children.Structure-activity relationship study of compounds binding to large amino acid transporter 1 (LAT1) based on pharmacophore modeling and in situ rat brain perfusion.LAT1-mediated prodrug uptake: a way to breach the blood-brain barrier?Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes-2.Quantitative insight into the design of compounds recognized by the L-type amino acid transporter 1 (LAT1).Plasma and cerebrospinal fluid concentrations of indomethacin in children after intravenous administration.Large amino acid transporter 1 (LAT1) prodrugs of valproic acid: new prodrug design ideas for central nervous system delivery.Free fatty acid receptor 1 (GPR40) agonists containing spirocyclic periphery inspired by LY2881835.Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes.Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes⁻4[Prodrugs]Piperazinylalkyl prodrugs of naproxen improve in vitro skin permeation
P50
Q28377598-79FF8370-252E-4A81-9974-D676561812DFQ30966309-BE23E034-1311-42AE-A729-FDB3CC26FFB5Q31152188-B71385D3-B5AF-4693-A04A-05EE7E52EAB1Q34198523-EE65F885-E133-42BE-8467-5CF1D6205575Q36792691-5ECF694B-D5C4-4354-B345-71DF01A66394Q37064858-816095FF-F5A0-43F7-8D0B-CF4525F7519AQ37150860-BED77218-6B9B-49DB-943F-0A6499E53A9AQ37294258-281B67C8-898D-4FA1-BA77-288369553FE2Q37889328-3F624141-9689-4E46-A003-EA7A673291D7Q38646118-1C90B52D-802B-4403-ABA2-C29D75F5BB2EQ38758331-AE03302C-BA94-4A9A-94AE-F56230A5B51EQ38944343-185B2009-DD48-4C7E-830E-9B930E1AC53CQ38948879-594801EB-CFFA-401C-8CB7-71255F1C60E6Q39414016-9D4C440D-FB50-4717-B11A-294BBAE5CF62Q39560250-9DF94272-F69C-4FAC-ABC4-3050AD03487FQ40321269-E4249832-5D61-4DD4-A30E-DD4885B0953CQ40647286-64999553-2089-46AC-8804-F5E2B87260E8Q42182796-4E95B857-9132-4662-9549-C573183E37B5Q42930696-E202506C-321A-46E1-9F85-B69F1D572675Q43869159-591FFFCA-CBB6-49B7-A7C0-F4D453C19BA3Q44928732-8A2413FF-0F75-4D35-B289-9041ECA45669Q45207272-7271670E-7B84-4FD3-9FEA-D03D1AE6B1B0Q45951082-77667BD8-441E-404E-A289-F304032A9C97Q45971445-43C51F73-43FA-4F48-B64F-ECBF0115FBBBQ46032183-C35B844A-8D6C-4046-A638-F9B674CDB890Q46755487-31D5EBBB-BDF6-4CA5-B479-AA38690284A6Q46793172-0383584D-7157-4329-A4FE-2B85AC8AB534Q46922577-CE224269-D2C8-4F59-AFA6-CADC2EC3F909Q46972313-58F6BD40-E60F-41B9-9CAF-EE67787510A8Q46973479-7CA8D067-B20E-41BF-B022-A4825DF05FE4Q48148305-2086337E-E6AF-4758-800D-735BD25B035EQ48337589-6ED7C37F-2D67-4BFD-9AB5-27D2A1D341F9Q48554104-F99843EB-49C4-4695-A0B5-AB671746CA98Q48633680-1F811F9A-08EE-4764-B53E-5F13DD627966Q49032961-80E70AD7-E492-44BA-A745-70BB4050A6A8Q51486989-D95B5B51-3C1F-4D40-A435-46B0DED95638Q53731615-6BDC2373-17B4-464D-98EB-2CBEC66B12BDQ61453558-C714509C-406F-48D9-8C6E-8AAEBE93BEC6Q73987359-4EC020D7-CF7E-41F4-A108-F790E29282F9Q74072244-2E53E166-C140-442D-B481-A78BB039088D
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Jarkko Rautio
@ast
Jarkko Rautio
@en
Jarkko Rautio
@es
Jarkko Rautio
@nl
Jarkko Rautio
@sl
type
label
Jarkko Rautio
@ast
Jarkko Rautio
@en
Jarkko Rautio
@es
Jarkko Rautio
@nl
Jarkko Rautio
@sl
prefLabel
Jarkko Rautio
@ast
Jarkko Rautio
@en
Jarkko Rautio
@es
Jarkko Rautio
@nl
Jarkko Rautio
@sl
P106
P21
P31
P496
0000-0003-2172-3980